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Abstract: Polycystic ovary syndrome (PCOS) is a heterogeneous condition characterized by
anovulation, hyperandrogenism, and polycystic ovaries. Because of the heterogeneous nature
of PCOS, women affected by the condition often require a customized approach for ovulation
induction when trying to conceive. Treating symptoms of PCOS in overweight and obese women
should always incorporate lifestyle changes with the goal of weight-loss, as many women with
PCOS will ovulate after losing 5%–10% of their body weight. On the other hand, other factors
must be considered including the woman’s age, age-related decline in fertility, and previous
treatments she may have already tried. Fortunately, multiple options for ovulation induction
exist for women with PCOS. This paper reviews specific ovulation induction options available
for women with PCOS, the benefits and efficacy of these options, and the related side effects
and risks women can anticipate with the various options that may affect treatment adherence.
The paper also reviews the recommended evidence-based strategies for treating PCOS-related
infertility that allow for incorporation of the patient’s preference. Finally, it briefly reviews
emerging data and ongoing studies regarding newer agents that have shown great promise as
first-line agents for the treatment of infertility in women with PCOS.
Keywords: polycystic ovary syndrome, anovulation, clomiphene citrate, letrozole, metformin,
obesity
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Stein and Leventhal initially described polycystic ovarian syndrome (PCOS) with
associated amenorrhea in 1935.1 They also described a strategy called an ovarian wedge
resection that seemed to be effective in treating the associated infertility. Since that
time, numerous descriptions and diagnostic criterion for the condition have emerged.
While it is fortunate that other treatment strategies have emerged, because varying
diagnostic criteria have been used to define PCOS over the years, it can be difficult
to determine the external validity of older published PCOS literature. More recently,
increasing attention to the exact definitions of PCOS and the quality of clinical studies investigating treatments for infertility related to PCOS have greatly advanced our
understanding of the nuances involved in treating PCOS-related infertility. The following sections review the evidence for the efficacy of various infertility treatment
strategies as well as the side effects and risks that may affect patient adherence. Overall,
this review examines the clinical experience and evidence for treating PCOS-related
infertility so that a treatment plan can be constructed that incorporates patient preference and is mutually satisfactory for the patient and the clinician.
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A current working definition
of PCOS
As previously mentioned, PCOS was originally described by
Stein and Leventhal in their classic paper published in the
American Journal of Obstetrics and Gynecology in 1935.1 In
this paper, Stein and Leventhal described seven women with
enlarged, polycystic ovaries, obesity, hirsutism, and chronic
anovulation. Recognizing the need to establish diagnostic
criteria for PCOS to allow for well-designed research and
clinical trials related to PCOS, an expert panel sponsored by
the National Institutes of Health (NIH) developed a widely
accepted definition for PCOS in 1990.2 This definition
included the following major criteria for defining PCOS:
hyperandrogenism and/or hyperandrogenemia, menstrual
dysfunction, and the exclusion of other known disorders.
While these criteria helped to clarify the standards for
diagnosis, treatment, and research, debate still existed on
the criteria that should be used to define the condition. In
2003, another expert conference was convened in Rotterdam,
The Netherlands. This conference was sponsored by the
European Society for Human Reproduction and Embryology and the American Society for Reproductive Medicine.
At this conference, the experts agreed that PCOS should be
defined by the presence of two of the following characteristics: oligo and/or anovulation, clinical and/or biochemical
signs of hyperandrogenism, and/or polycystic ovaries on
an ultrasound. This definition was broader than the NIH
criteria and placed less emphasis on the hyperandrogenism
requirement. More recently, the Androgen Excess and PCOS
Society, an organization comprising international experts in
the area of PCOS, published a report outlining the following characteristics as being key to the diagnosis of PCOS:
hyperandrogenism (clinical and/or biochemical), ovarian
dysfunction (oligo-anovulation and/or polycystic ovaries),
and the exclusion of related disorders. In this definition,
the experts re-established hyperandrogenism as the key to
PCOS diagnosis.
While some of the debate surrounding the definition of
PCOS may be related to semantics for research purposes
rather than clinical care, establishing clear diagnostic criteria
for PCOS is necessary for embarking on sophisticated mechanistic research involving the study of PCOS and for applying
the results of clinical trials to individual patients.
Regardless of the criteria used to diagnose women
affected by PCOS, it is the most common endocrinopathy
affecting women of reproductive age. Somewhere
between 6%–8% of women are affected by this syndrome
worldwide. 3 In addition to the hyperandrogenism and
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a novulation/oligomenorrhea that characterize the condition,
depression, and long-term risks for the development of
endometrial cancer, diabetes, and cardiovascular disease are
also significant risks.4–6 If no work up has been performed
on a woman presenting with a clinical picture of PCOS,
we will typically screen these women for other causes of
ovulation disorders including thyroid disease, Cushing’s
syndrome, and premature ovarian failure when appropriate.
We also typically check a serum testosterone level (total),
and a 17-hydroxyprogesterone value in addition to routine
screening tests recommended by current guidelines including a complete serum lipid panel and a 2 hour, 75 gram oral
glucose tolerance test.6

Opportunity for preconception
counseling in infertile women
with PCOS: an opportunity
for education and improved lifestyle
for a healthier outcome
Screening for glucose intolerance and
diabetes – to take metformin or not?
Current guidelines for treating women with PCOS recommend screening for glucose intolerance.6 Of the available
options for screening (fasting glucose, hemoglobin A 1c,
and the 2 hour, 75 gram oral glucose tolerance test), the
2 hour, 75 gram oral glucose tolerance test may be the most
sensitive means of detecting glucose intolerance.5,7 This
method may also be helpful for determining if a woman is a
pregestational diabetic. For women who are not diabetic, but
who are glucose intolerant, the addition of metformin may
lead to improved insulin sensitivity and a better metabolic
profile and response to clomiphene citrate (CC) for ovulation induction.8 Metformin will likely have no benefit for
non-obese women with PCOS who do not show glucose
intolerance after screening. Whether or not metformin reduces
the risk of developing gestational diabetes once pregnancy
occurs is unknown although more recent data suggests that
it does not.9 Including this background information for
women when counseling them on their treatment options for
ovulation induction may be helpful as metformin was touted
as the mainstay of PCOS treatment by many for years, but
unfortunately, many women experience gastrointestinal side
effects such as nausea and diarrhea. Due to the risks of associated lactic acidosis, metformin should be started at a low
dose and built up over time, and only if women are proven to
have normal renal and hepatic functioning. We recommend
starting at 500 mg po daily for one week with an additional
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500 mg daily per week until a 2000 mg daily dose is reached.
The extended release formulation may be beneficial for
women who have difficulty with that dosage level.

Weight loss
While infertility is an emotionally difficult condition for
any couple to face, it offers an important opportunity
for thorough preconception counseling and intervention
for couples hoping to conceive. In women with PCOS,
this opportunity can be especially beneficial as these
women face increased risks of gestational diabetes and
preeclampsia during pregnancy. These risks, along with the
anovulation associated with PCOS, are often exacerbated
by the excess body weight that often accompanies PCOS.
Overweight and obese women with anovulation/oligomenorrhea and PCOS will often ovulate spontaneously
after losing only 5%–10% of their body weight. When
setting a timeline and goal for weight loss, it is important
to keep the woman’s age in mind as fertility decreases
more rapidly after age 35. Morbidly obese women with
a body mass index (BMI) of 40 kg/m2 or greater may
require greater weight loss.10 For many women, clinically
significant weight loss may be difficult to achieve and
sustain. Encouraging partner involvement in the weight
loss plan may be helpful. Reviewing previous attempts at
weight loss with women and encouraging them to consider
commercial weight loss programs may also be beneficial
along with a referral to a dietician and an exercise facility.
Setting a goal for weight loss and a plan for follow up are
also important. This is also an opportune time to review
the long-term health risks associated with obesity and
PCOS such as type 2 diabetes, endometrial cancer, and
cardiovascular disease. Reviewing these risks with women
at this crucial time may encourage them to act.
For obese women with PCOS who are over 40 kg/m2 or
women who are 35 kg/m2 with co-morbidities like diabetes,
bariatric surgery may be an option for achieving sustainable
weight loss. Again, it may be necessary for these women to
lose more than 5%–10% of their body weight to see improvements in ovulation. On the other hand, bariatric surgery is
not without risks and requires a commitment that many
people are not willing to make. Nevertheless, this option
is worth mentioning to women who qualify, along with a
discussion of the time commitment required. Most surgeons
recommend that women wait for a period of one year after
bariatric surgery prior to conception so that the maximum
benefit of the weight loss associated with the procedure can
be achieved. Many women have successfully conceived prior
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to the one-year wait period and this may be reasonable for
older patients.11 It is important to warn patients that while
they may achieve successful weight loss, fertility treatments
may still be required.12
Given the time commitment required for weight loss,
a discussion of patient age and baseline fertility is warranted since delaying fertility treatment may be detrimental
to a woman’s prospects for childbearing. Recent crosssectional studies by the Society for Assisted Reproductive
Technologies (SART) present convincing evidence on the
impact of obesity on fertility versus the impact of age. In
these studies, researchers have shown that increasing obesity is associated with decreased chances of conception in
women younger than age 35 undergoing assisted reproductive
technologies (ART).13 Conversely, in women over the age
of 35, obesity has less of an impact on the success of ART
and age becomes the overriding factor.13,14 While attempts
at weight loss and lifestyle improvements should never be
discouraged in overweight and obese women, women must
be fully informed of the realistic expectations they may have
for fertility with increasing age.

Modifiable risk factors: dietary
interventions
Emerging epidemiologic data from the Nurses’ Health
Study II (NHSII) suggest that certain foods may be associated with ovulation disorders like PCOS.15 While controlling for BMI, nutritional epidemiologists involved with
NHSII have demonstrated that certain dietary choices may
be associated with higher risks of anovulation. The results
of these epidemiologic investigations led by nutritional
epidemiologist, Jorge Chavarro, MD, PhD, suggest that
saturated animal fats and trans-fats found in commercially
baked goods and some fried fast foods are associated
with ovulatory infertility while fats found in foods such
as salmon, tuna, and nut sources may be beneficial to
promoting ovulatory function.16 Dr Chavarro’s work also
shows that foods containing refined sugars are detrimental
to ovulatory fertility while carbohydrate-rich foods with a
lower glycemic index may be beneficial.17 Finally, these
studies have shown that daily multi-vitamin use may be
beneficial for women with PCOS-related infertility along
with supplemental iron intake.18,19 Given that folic acid is
an important supplement for any woman of reproductive
age for preventing neural tube defects, a multi-vitamin
containing folic acid should always be encouraged.
Education regarding patient-modified interventions such as
these may be empowering for some patients and should be
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discussed along with the disclaimer that prospective trials
incorporating dietary recommendations like these have yet
to be completed; therefore, their impact on ovulation and
reproductive outcomes is yet to be determined.

When time runs out: moving
on from lifestyle intervention
to ovulation induction
As mentioned, fertility declines with age. This decline
increases rapidly after age 35. It has been suggested in the
SART literature that women younger than 35 aim for a BMI
of less than 30 kg/m2.20 Women over age 35 should aim for a
BMI of less than 35 kg/m2. For these women, it is unknown
whether achieving a BMI of less than 35 kg/m2 will lead to
an improved response to fertility treatment or a healthier
pregnancy outcome. It is both realistic and reasonable to
propose fertility treatment for otherwise healthy overweight
and obese women with PCOS who have tried to lose weight
unsuccessfully, and this approach is supported by the Ethics
Committee of the American Society for Reproductive
Medicine.21 While obesity is associated with decreased
success in fertility treatments22 and increased risks of adverse
pregnancy outcomes, a BMI at which it is unsafe to provide
fertility treatments has not been established and likely
never will be since there are numerous examples of women
with excessive BMIs who have successfully conceived and
delivered. Ultimately, a conversation between the physician
and patient must take place to determine the right course of
action and to understand the evidence regarding the competing
risks of time required for weight loss and the effects of age
on fertility and response to fertility treatment.

The data for ovulation induction
in women with PCOS: past, present
and future
Treatments of the past: wedge resection
and ovarian drilling
As mentioned in the introduction, Stein and Leventhal
described wedge resection for ovulation induction in women
with PCOS.1 While this method can help women achieve
spontaneous ovulation, it is invasive with significant risk
of blood loss during surgery, post-operative adhesion formation, and time-loss for recovery. Ovarian drilling has
also been shown to be efficacious in inducing spontaneous
ovulation and pregnancy.23–25 It offers an advantage over
ovarian wedge resection as it is less likely to be associated
with significant blood loss, and is easily conducted via a
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laparoscopic technique. This method is helpful in cases
where women are resistant to ovulation induction with oral
medications and want to avoid gonadotropin injections.
However, it is also associated with pelvic adhesion formation
and decreased ovarian reserve over time as a portion of the
ovary is destroyed through the drilling process. Both of these
surgical interventions have been largely replaced with oral
ovulation induction methods with gonadotropin injections,
while ARTs are reserved for women who fail to ovulate or
conceive with oral medications.

First-line treatment: CC, metformin,
or both?
CC is a convenient, accessible, and relatively inexpensive
treatment that has been a mainstay for ovulation induction in
women with PCOS for over 40 years. Unfortunately, a fraction of women with PCOS are resistant to CC. In the 1990s,
metformin was identified as a solution to such cases and
gained popularity as a first-line alternative to CC because it
was thought to improve metabolic functioning while decreasing the risk PCOS in patients who faced developing gestational diabetes during pregnancy.8,9,26 Numerous studies have
emerged that compare the two agents for ovulation induction
with disparate results.27,28 Finally, the NIH-sponsored Reproductive Medicine Network (NIH-RMN) undertook a large,
multi-centered trial comparing CC, metformin, and both as
agents for ovulation induction.29 In this intention-to-treat
trial, CC was clearly better as a first-line agent for achieving pregnancy and live birth when compared to metformin
alone. The combination of CC with metformin was equivocal,
although there was some evidence that the combination arm
may have helped in PCOS patients with morbid obesity. Some
have argued that it was poor compliance with metformin
therapy that resulted in the superior results of the CC-alone
arm,30 but a secondary analysis of the data has demonstrated
that adherence in both the metformin-only and combinedmetformin-CC arms was within the reported expectations
for clinical trials.31 The authors of the study concluded that
failure to comply with metformin dosing was not the reason
for low ovulation and pregnancy rates in the metformin arms
of the trial.
Common side-effects associated with CC include hot
flashes and labile mood. Visual disturbances and headaches
should warrant discontinuation and consideration of switching to an alternative agent for ovulation induction. We
recommend starting with a daily dose of CC 50 mg daily
cycle for 3–7 day with a luteal phase progesterone level to
document ovulation. If the progesterone value is ,2 ng/mL
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and the woman’s cycle is longer than 35 days with a negative
urine pregnancy test, we recommend inducing menses and
proceeding with another cycle of CC and increasing the dose
by an additional 50 mg cycle for 3–7 days. These steps are to
be repeated until ovulation is achieved to a maximum dose of
150 mg to 200 mg depending on the associated side effects.
This process can be frustrating and it is often important to
encourage women to be persistent if ovulation is not achieved
in the first one or two cycles to help with adherence.31
For women who are resistant to ovulation induction with
CC alone, the addition of metformin may be beneficial.26 In
a recent publication, we demonstrated that initial concomitant treatment with CC and metformin may be superior to
CC alone.32 We argue that the sample size employed in the
NIH-RMN trial was not large enough to detect the clinically significant difference that may exist in treating women
with CC alone versus CC and metformin together.33 Again,
screening for insulin resistance in women with PCOS prior to
treatment may indicate which women will benefit from initial
concomitant treatment with both CC and metformin.
As previously discussed, metformin – labeled by some
as “Vitamin M” – was the first-line for treating infertility in
women with PCOS.34 Due to the heterogeneous nature of the
PCOS, not all women will respond to metformin; therefore, it
should be reserved for women with proven insulin-resistance.
Again, we recommend a 2 hour, 75 gram oral glucose tolerance test for screening. We also recommend that it not be
used alone in the treatment of PCOS-related infertility as the
results of the NIH-RMN trial described above clearly demonstrate the inadequacy of metformin alone when compared to
CC alone and CC and metformin together. For women who
are insulin-resistant, we recommend an approach of CC at
50 mg daily cycle for 3–7 days with a daily dose of 2000 mg
of metformin. As outlined above, metformin should be started
at a daily dose of 500 mg and built up over a period of weeks
to reach the 2000 mg dose.

Letrozole as the future first-line
treatment
Aromatase inhibitors prevent the aromatization of testosterone to estrogen and are used primarily as adjunctive agents
to treat breast cancer. The first report of letrozole’s efficacy at
inducing ovulation in women with PCOS emerged in 2001.35
Letrozole is relatively well tolerated in terms of the associated side effects such as gastrointestinal disturbances and hot
flashes. Furthermore, letrozole has a shorter half-life than CC.
When used for ovulation induction, letrozole is associated
with a thicker endometrium compared to CC and multiple
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gestations may be less common. While letrozole appears to be
efficacious at inducing ovulation, it is yet to be demonstrated
in adequately designed clinical trials whether it results in
higher pregnancy rates and an improved chance at singleton
pregnancy compared to CC.36–38 Fortunately, the RMN has
initiated a large, multi-centered trial to investigate the effect
of letrozole versus CC in infertile women with PCOS.39 The
primary outcome of this trial is live birth. Important secondary outcomes include, among others, singleton pregnancy,
incidence of first trimester fetal demise, time to pregnancy,
quality of life while on treatment, and cost-effectiveness.
Letrozole is currently reserved for women with PCOSrelated infertility who do not respond to ovulation induction
with CC or who cannot tolerate its side effects. We typically
prescribe 5 mg of letrozole for a 3–7 day cycle with a midluteal serum progesterone level to document ovulation.
If ovulation is not achieved with lifestyle interventions
or oral agents or a woman fails to conceive in a given time
frame, we recommend moving on to a more aggressive
treatment. We do not recommend treating women with
ovarian wedge resection or laparoscopic ovarian drilling. We
will typically treat a woman with ovulation induction agents
for up to six ovulatory cycles provided that tubal patency and
a reasonable semen analysis have been noted. In general, if a
woman with PCOS is not pregnant after six ovulatory cycles
and she is ready to move on to other treatment options, we
will do so.

When all else fails: controlled
ovarian hyperstimulation and
in vitro fertilization
Controlled ovarian hyperstimulation
with injectable medications
We reserve controlled ovarian hyperstimulation (COH) for
women with PCOS who have failed ovulation induction with
oral agents. Our goal in treating PCOS patients with COH
is to achieve monofollicular development. To achieve this
goal, a lower starting dose of gonadotropin is recommended
compared to what is typically used in women with other
indications for COH. We will typically start women with
PCOS with 75 units daily of a gonadotropin product with a
serum estradiol level planned for the morning of the fourth
treatment day. Women must be warned of the risk of cycle
cancellation if too many follicles are recruited, the risk of
ovarian hyperstimulation (OHSS), and the risk of higher
order multiple gestation pregnancy if they choose this mode
of treatment.25 There are a number of factors that may affect a
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woman’s decision whether or not to pursue COH or skip COH
and move directly to in vitro fertilization. These include the
costs of the procedures at an individual center, insurance coverage requirements if she has infertility insurance benefits,
and access to centers that provide in vitro fertilization because
centers with facilities for IVF are often concentrated in areas
of high population density and women may have to travel for
hours to get to one of these facilities.40 Despite these factors,
it may be reasonable for some woman to consider IVF over
COH given the higher success rates associated with IVF and
the option for single embryo transfer that exists with lower
risks for multiple gestation pregnancy. Given the higher
costs associated with IVF, it may be helpful to discuss IVF
with women who have PCOS-related infertility early on
so they may start to plan ahead should they need to utilize
these services.

ART: in vitro fertilization
IVF offers all women the most effective mode of achieving
pregnancy in a single cycle.41 On the other hand, IVF may
be cost-prohibitive for some women, it is time consuming,
and is associated with risks related to OHSS, anesthesia, and
surgical complications such as bleeding and bowel/bladder
injury. For women with PCOS who have not responded to
treatment with more conservative options, or for women
with PCOS who have other conditions that require IVF
(blocked fallopian tubes, male partner with low sperm
counts, or genetic conditions amenable to intervention with
preimplantation genetic diagnosis testing) the benefits of IVF
may outweigh the risks. For any woman considering IVF
treatment, we recommend consulting the SART to obtain
information regarding facilities that provide IVF services.42
We also recommend investigating the Centers for Disease
Control website on ART for additional information regarding
factors other than success rates to consider when choosing an
IVF facility.43 Couples will often consider only one to two
cycles of IVF so it is imperative that they are well informed
of the success rates in various IVF facilities and the qualifications of their providers.
A recent study found that centers with high-performing
IVF programs share common qualities that may be helpful
for patients and referring physicians.44 One of these commonalities is the selective use of blastocyst embryo transfer
which may improve selection for single embryo transfer in
IVF. Single embryo transfer may be an especially important
option for women with PCOS as they may be at increased
risk for pregnancy complications if they were to conceive
with multiple gestations given their predisposition for gesta-
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tional diabetes and preeclampsia. Medical societies like the
American Society for Reproductive Medicine and patient
advocate groups like RESOLVE are also helpful for couples
seeking additional information.45,46
Table 1 compares the approximate success rates of various oral ovulation induction agents, COH, and IVF along
with their associated side-effects, risks, and relative costs.

Patient treatment preferences
for PCOS-related infertility
Unfortunately, the data are sparse when it comes to incorporating patient preference in the management of PCOSrelated infertility. We found one article when we performed
a MEDLINE search for published data using the keywords,
“patient preference” and “polycystic ovary syndrome.” This
article entitled, “Treatment preferences and trade-offs for
ovulation induction in CC-resistant patients with polycystic
ovary syndrome,” assessed the preferences and trade-offs for
laparoscopic electrocautery of the ovaries relative to ovulation induction with FSH injections in women with PCOS
who were resistant to ovulation induction with CC.47 The
data presented in this article suggest that women are open
to discussing different treatment options, while weighing the
risks and benefits of each.
A discussion of the available options should include a
thorough explanation of normal menstrual cycles and ovulation and an explanation of how the various strategies work,
their associated risks and benefits, and their cost and efficacy.
Unfortunately, inducing ovulation in women with PCOS
often requires a trial-and-error process with different medications and lifestyle modifications. The recommendations
outlined in this review are consistent with an evidence-based
approach to managing PCOS-infertility in a timely, safe,
and effective manner. Greater transparency regarding the
common difficulties encountered when inducing ovulation
in women with PCOS will likely be helpful for improving
patient compliance with treatment, although this has not been
studied specifically in women with PCOS.
When it comes to patient preference in the management
of PCOS-related infertility, the bottom line is that women
with infertility ultimately want to conceive.47 Personalized
treatment algorithms are often dictated by cost, insurance
coverage for fertility treatment, and the effectiveness of
the various medications in individuals. How these various
factors drive a woman’s treatment trajectory is yet to be
determined, but it is likely that women’s choices are often
driven by cost and the out-of-pocket-expenses associated
with the strategies. In our synthesized data incorporating
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∼15%

∼25%

∼25%

∼50%

∼30%

∼20%

∼40%

∼30%

∼65%

∼35%

Society for Assisted
Reproductive Technology:
for ovulatory dysfunction which
includes PCOS: in women
younger than 35, 53% chance
of pregnancy with 34% chance
of live birth with twins
Varies depending on degree
of weight loss

Letrozole

Controlled ovarian
hyperstimulation

Laparoscopic drilling

In vitro fertilization

Others
• Lifestyle intervention
with diet and exercise
in overweight and obese
women
• Bariatric surgery for obese
women who meet criteria

∼20%

∼30%

Clomiphene citrate (up to
6 months of treatment)
Metformin (1500–2000 mg
per day with up to
6 months of treatment)
Clomiphene citrate plus
metformin (with up to
6 months of treatment)

Varies depending on degree
of weight loss

Society for Assisted
Reproductive Technology:
for ovulatory dysfunction
which includes PCOS: 46%
chance of live birth (44.3–
47.3 reliability range)

Probability of
live birth

Probability of
pregnancy

Method

Table 1 Important factors to consider in treating PCOS-related infertility23–25,27,28,31,35–37

Varies

Up to $20,000
per cycle

Varies

Up to $3000
per cycle

Up to $200
per month

,$100 per
month

Approximate
cost per cycle

Ovarian hyperstimulation syndrome;
multiple gestations; limited access; time
commitment for ultrasound monitoring
and injections
Risks of surgery and general anesthesia;
unknown long-term effects on ovarian
function, possible adhesion formation
Ovarian hyperstimulation syndrome;
limited access; time commitment for
ultrasound monitoring and injections;
multiple gestations: 34% of women had
twins, and 1.8% of women had triplets
or more, despite 13% of cycles with
single embryo transfer
Time commitment required may result
in decreased fertility; require greater
amount of weight loss in morbidly
obese women; compliance

Multiple gestations; nausea; gastrointestinal
distress; ∼7% discontinuation versus
2% in clomiphene citrate or metformin
alone; direct antiestrogenic effects such
as thinning of endometrium or thickening
of cervical mucus
Nausea; flushing; constipation; weight gain

Nausea; gastrointestinal distress

Multiple gestations

Common side effects &
risks

Improvements in other metabolic
factors; lower risk for multiple
gestations

Lower risk of multiple gestation;
consecutive ovulations occur without
need for further treatment
Efficacy

Cost; accessibility, lower risk
of multiple gestations; no direct
antiestrogenic effects such as thinning
of endometrium or thickening of
cervical mucus
Efficacy

Cost; accessibility; lower risk of
multiple gestations; possible other
metabolic benefits
Cost; accessibility; metabolic
benefits; option for women who are
resistant to clomiphene alone

Cost; accessibility

Benefits over other methods
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side effects and efficacy into decisions for treating women
with PCOS, an approach that combines metformin and CC
for initial treatment was the best initial therapy for ovulation induction in women with PCOS, although letrozole was
included in the study. Forthcoming data from the NIH-RMN
reports will help inform the future use of letrozole in this
population.

Keeping women informed, keeping
the dialog open, and presenting a
global perspective on PCOS-related
infertility treatment
Because of the heterogeneous nature of the presentation of
PCOS, it often takes some troubleshooting and trial and error
to determine the best course of action. As mentioned above,
we recommend screening women with PCOS for related comorbidities as outlined by practice guidelines.6 This screening
includes checking women for glucose intolerance. If a woman
is glucose intolerant, she may benefit from treatment with
metformin, but should be warned of side effects and should
never be treated with metformin alone if ovulation induction
and pregnancy is the goal. If a woman is overweight or obese,
lifestyle intervention with the goal of weight loss is also recommended, but is not always rational if a woman has failed
numerous attempts at weight loss in the past or if she is older
than 35 years. CC is the proven first-line agent for ovulation
induction in women with PCOS, but we are still anticipating
the results from the NIH-RMN trial as letrozole may prove
to be equally, if not more, efficacious at achieving pregnancy
and live birth with reduced risk of multiple gestations.39 If
these less expensive, easily accessed options prove ineffective,
COH or IVF are possible although they are associated with
increased costs, increased time commitment, and increased
risks of complications such as ovarian hyperstimulation and
multiple gestations.
The good news is infertile women with PCOS have
options. It is up to us to ensure that we are fully versed on these
options and that we are proactive in educating our patients
to ensure that they do not miss the window of opportunity to
achieve their family-building goals. If a general practitioner
does not have the time to spend counseling and managing
women struggling with PCOS-related infertility, a referral
to a specialist in reproductive medicine is appreciated by all
the parties involved.
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